Atai Life Sciences is a clinical-stage biopharmaceutical company developing novel therapeutics for mental health conditions. They are advancing psychedelic and non-psychedelic compounds, including DMT, MDMA, and psilocin, to offer rapid-acting and durable relief for patients with treatment-resistant depression, social anxiety disorder, and cognitive impairment.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+7Founders
Product
Problem
Patients with mental health disorders, including depression, social anxiety disorder, and cognitive impairment associated with schizophrenia, often face limited or ineffective treatment options. Existing therapies may not provide rapid-acting or durable relief, leaving a significant unmet need in patient care.
Solution
Atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for mental health conditions. The company's strategy involves identifying and advancing compounds that offer rapid-acting, effective, and durable solutions. Atai's pipeline includes both psychedelic and non-psychedelic programs, targeting indications with substantial unmet patient needs. By leveraging a deep understanding of neurobiology and clinical development, Atai aims to transform patient outcomes and improve the standard of care in mental health.
Target Audience
The primary target audience includes patients suffering from mental health disorders such as treatment-resistant depression, social anxiety disorder, and cognitive impairment associated with schizophrenia, as well as healthcare providers and researchers in the psychiatric field.
Features
- **VLS-01 (buccal film DMT):** A proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) for treatment-resistant depression (TRD), designed for rapid, robust, and durable efficacy within a two-hour treatment paradigm.
- **EMP-01 (R-MDMA):** An oral formulation of the R enantiomer of 3,4-Methylenedioxymethamphetamine (MDMA) for social anxiety disorder (SAD), engineered for improved tolerability and reduced adverse effects compared to racemic MDMA.
- **Novel 5-HT2A Receptor Agonists:** Development of non-hallucinogenic neuroplastogens targeting the 5-HT2A receptor.
- **BPL-003 (mebufotenin benzoate):** A psychedelic compound being investigated for treatment-resistant depression, currently in Phase 2 clinical trials.
- **ELE-101 (Psilocin):** A psilocin-based therapeutic candidate for major depressive disorder, undergoing Phase 1 clinical evaluation.
- **RL-007:** A pro-cognitive neuromodulator in an oral formulation, investigated for cognitive impairment associated with schizophrenia, demonstrating consistent cognitive effects and good tolerability in over 500 participants.